Related references
Note: Only part of the references are listed.Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Constantine S. Tam et al.
BLOOD (2009)
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
Owen A. O'Connor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Progress in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study
Oliver Weigert et al.
LEUKEMIA & LYMPHOMA (2009)
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies
P. Martin et al.
ANNALS OF ONCOLOGY (2008)
Statistical power and validation of the MIPI - Response
Eva Hoster et al.
BLOOD (2008)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
Yuhong Zhou et al.
CANCER (2008)
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
Elena Hartmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma
K. Sue Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognosis of mantle cell lymphoma: is it all about proliferation?
Oliver Weigert et al.
LEUKEMIA & LYMPHOMA (2008)
Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
Olaf Determann et al.
BLOOD (2008)
Central nervous system involvement in mantle cell lymphoma
A. Ferrer et al.
ANNALS OF ONCOLOGY (2008)
Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
O. Weigert et al.
LEUKEMIA (2007)
A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150
A. Belch et al.
ANNALS OF ONCOLOGY (2007)
Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309
Elena Hartmann et al.
HAEMATOLOGICA (2007)
High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)
Rudolf Weide et al.
LEUKEMIA & LYMPHOMA (2007)
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival
Adrian Wiestner et al.
BLOOD (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gastrointestinal involvement in mantle cell lymphoma:: A prospective clinic, endoscopic, and pathologic study
Antonio Salar et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis
Kristen N. Ganjoo et al.
LEUKEMIA & LYMPHOMA (2006)
Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity
SJ Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
C Pott et al.
BLOOD (2006)
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:: results of a randomised phase III trial (OSHO# 19)
M Herold et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
C Thieblemont et al.
CANCER (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pathogenesis of mantle-cell lymphoma:: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
V Fernàdez et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Current treatment approaches for mantle-cell lymphoma
TE Witzig
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radioimmunotherapy for Non-Hodgkin's Lymphoma
Arati V. Rao et al.
CLINICAL MEDICINE & RESEARCH (2005)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies
RZ Orlowski et al.
BLOOD (2005)
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP
DW Thomas et al.
LEUKEMIA & LYMPHOMA (2005)
Nuclear factor-κB inhibitors as sensitizers to anticancer drugs
C Nakanishi et al.
NATURE REVIEWS CANCER (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-Cell non-Hodgkin's lymphoma
A Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK)
M Ghielmini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
JF DiJoseph et al.
BLOOD (2004)
Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis
J Mangel et al.
ANNALS OF ONCOLOGY (2004)
Mantle cell lymphoma: established therapeutic options and future directions
G Lenz et al.
ANNALS OF HEMATOLOGY (2004)
The role of fludarabine in the treatment of follicular and mantle cell lymphoma
G Lenz et al.
CANCER (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
H Kaufmann et al.
BLOOD (2004)
Transplantation in patients with diffuse mantle cell lymphoma in first disease remission the prognostic value of β2-microglobulin and the tumor score
IF Khouri et al.
CANCER (2003)
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma
R M'kacher et al.
ONCOGENE (2003)
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)
AM Gianni et al.
BLOOD (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Cyclpoxygenase-2 inhibitors in colorectal cancer
J Stoehlmacher et al.
SEMINARS IN ONCOLOGY (2003)
Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada clinical trials group
CT Kouroukis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
N Mitsiades et al.
BLOOD (2003)
Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma
A Younes et al.
CLINICAL LYMPHOMA (2003)
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
JE Romaguera et al.
CANCER (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma:: chemotherapy versus chemotherapy plus rituximab
M Herold et al.
ANNALS OF HEMATOLOGY (2003)
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy
G Freyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
IF Khouri et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation
SP Robinson et al.
BLOOD (2002)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma
MJ Rummel et al.
EUROPEAN JOURNAL OF CANCER (2002)
Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma
SL Chua et al.
LEUKEMIA & LYMPHOMA (2002)
Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells
ZA Nagy et al.
NATURE MEDICINE (2002)
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
AK Gopal et al.
BLOOD (2002)
Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma:: a prospective study
F Lefrère et al.
LEUKEMIA (2002)
Cisplatin, fludarabine, and cytarabine - A novel, pharmacologically designed salvage therapy for patients with refractory histologically aggressive or mantle cell non-Hodgkin lymphoma
JF Seymour et al.
CANCER (2002)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
OM Howard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
BJ Cohen et al.
LEUKEMIA & LYMPHOMA (2001)
Allogeneic bone marrow transplantation for refractory mantle cell lymphoma
N Kröger et al.
ANNALS OF HEMATOLOGY (2000)
The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: a new look at an old method
A Safwat
RADIOTHERAPY AND ONCOLOGY (2000)
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
PL Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
